nodes	percent_of_prediction	percent_of_DWPC	metapath
Pranlukast—NFKB1—Thalidomide—hematologic cancer	0.271	0.494	CbGbCtD
Pranlukast—TNF—hematologic cancer	0.206	1	CbGaD
Pranlukast—TNF—Thalidomide—hematologic cancer	0.0815	0.148	CbGbCtD
Pranlukast—ABCC2—Daunorubicin—hematologic cancer	0.018	0.0327	CbGbCtD
Pranlukast—CYP2C9—Bexarotene—hematologic cancer	0.0103	0.0187	CbGbCtD
Pranlukast—ABCC2—Irinotecan—hematologic cancer	0.00859	0.0156	CbGbCtD
Pranlukast—CYP2C9—Idarubicin—hematologic cancer	0.00852	0.0155	CbGbCtD
Pranlukast—ABCC2—Vinblastine—hematologic cancer	0.00764	0.0139	CbGbCtD
Pranlukast—ABCC2—Vincristine—hematologic cancer	0.00751	0.0137	CbGbCtD
Pranlukast—ABCC2—Cisplatin—hematologic cancer	0.007	0.0127	CbGbCtD
Pranlukast—ABCC2—Etoposide—hematologic cancer	0.00688	0.0125	CbGbCtD
Pranlukast—CYP2C9—Bortezomib—hematologic cancer	0.0063	0.0115	CbGbCtD
Pranlukast—CYP3A4—Bexarotene—hematologic cancer	0.00598	0.0109	CbGbCtD
Pranlukast—RNASE3—hematopoietic system—hematologic cancer	0.00571	0.0869	CbGeAlD
Pranlukast—ABCC2—Dexamethasone—hematologic cancer	0.00566	0.0103	CbGbCtD
Pranlukast—CYP3A4—Busulfan—hematologic cancer	0.00556	0.0101	CbGbCtD
Pranlukast—CYP3A4—Lomustine—hematologic cancer	0.00556	0.0101	CbGbCtD
Pranlukast—CYP2C9—Thalidomide—hematologic cancer	0.00549	0.01	CbGbCtD
Pranlukast—CYP2C9—Teniposide—hematologic cancer	0.00524	0.00954	CbGbCtD
Pranlukast—IL5—hematopoietic system—hematologic cancer	0.00519	0.0789	CbGeAlD
Pranlukast—CYP3A4—Thiotepa—hematologic cancer	0.00496	0.00902	CbGbCtD
Pranlukast—CYP2C9—Ifosfamide—hematologic cancer	0.00483	0.0088	CbGbCtD
Pranlukast—ABCC2—Doxorubicin—hematologic cancer	0.00469	0.00854	CbGbCtD
Pranlukast—CYP2C9—Imatinib—hematologic cancer	0.00462	0.00841	CbGbCtD
Pranlukast—ABCC2—Methotrexate—hematologic cancer	0.00455	0.00828	CbGbCtD
Pranlukast—CYP2C9—Nilotinib—hematologic cancer	0.0042	0.00764	CbGbCtD
Pranlukast—CYP3A4—Methoxsalen—hematologic cancer	0.00385	0.00702	CbGbCtD
Pranlukast—RNASE3—blood—hematologic cancer	0.00379	0.0576	CbGeAlD
Pranlukast—CYP3A4—Bortezomib—hematologic cancer	0.00367	0.00667	CbGbCtD
Pranlukast—RNASE3—bone marrow—hematologic cancer	0.00366	0.0557	CbGeAlD
Pranlukast—CYP3A4—Daunorubicin—hematologic cancer	0.00351	0.00638	CbGbCtD
Pranlukast—IL5—blood—hematologic cancer	0.00344	0.0523	CbGeAlD
Pranlukast—RNASE3—lung—hematologic cancer	0.00332	0.0505	CbGeAlD
Pranlukast—CYP3A4—Cytarabine—hematologic cancer	0.00309	0.00563	CbGbCtD
Pranlukast—CYP3A4—Teniposide—hematologic cancer	0.00305	0.00555	CbGbCtD
Pranlukast—MUC2—gonad—hematologic cancer	0.00303	0.0461	CbGeAlD
Pranlukast—IL5—lung—hematologic cancer	0.00301	0.0458	CbGeAlD
Pranlukast—IL5—testis—hematologic cancer	0.00284	0.0433	CbGeAlD
Pranlukast—CYP3A4—Ifosfamide—hematologic cancer	0.00281	0.00512	CbGbCtD
Pranlukast—CYP3A4—Imatinib—hematologic cancer	0.00269	0.00489	CbGbCtD
Pranlukast—TNF—blood—hematologic cancer	0.00264	0.0402	CbGeAlD
Pranlukast—CYP3A4—Ruxolitinib—hematologic cancer	0.00253	0.0046	CbGbCtD
Pranlukast—CYP3A4—Nilotinib—hematologic cancer	0.00244	0.00444	CbGbCtD
Pranlukast—CYP3A4—Vinorelbine—hematologic cancer	0.00242	0.00441	CbGbCtD
Pranlukast—CYP2C9—Cisplatin—hematologic cancer	0.00235	0.00428	CbGbCtD
Pranlukast—MUC2—lung—hematologic cancer	0.00232	0.0352	CbGeAlD
Pranlukast—NFKB1—hematopoietic system—hematologic cancer	0.00227	0.0346	CbGeAlD
Pranlukast—CYSLTR1—hematopoietic system—hematologic cancer	0.00223	0.034	CbGeAlD
Pranlukast—CYP3A4—Triamcinolone—hematologic cancer	0.00221	0.00403	CbGbCtD
Pranlukast—MUC2—testis—hematologic cancer	0.00219	0.0333	CbGeAlD
Pranlukast—CYP3A4—Dasatinib—hematologic cancer	0.00216	0.00393	CbGbCtD
Pranlukast—CYP3A4—Mitoxantrone—hematologic cancer	0.00213	0.00388	CbGbCtD
Pranlukast—IL5—lymph node—hematologic cancer	0.00206	0.0314	CbGeAlD
Pranlukast—CYP2C9—Dexamethasone—hematologic cancer	0.0019	0.00346	CbGbCtD
Pranlukast—CYP3A4—Betamethasone—hematologic cancer	0.0019	0.00346	CbGbCtD
Pranlukast—CYP3A4—Prednisolone—hematologic cancer	0.00187	0.00341	CbGbCtD
Pranlukast—CYP3A4—Prednisone—hematologic cancer	0.00177	0.00322	CbGbCtD
Pranlukast—NFKB1—gonad—hematologic cancer	0.00173	0.0263	CbGeAlD
Pranlukast—CYP3A4—Irinotecan—hematologic cancer	0.00168	0.00305	CbGbCtD
Pranlukast—TNF—lymph node—hematologic cancer	0.00158	0.0241	CbGeAlD
Pranlukast—NFKB1—blood—hematologic cancer	0.00151	0.0229	CbGeAlD
Pranlukast—CYP3A4—Vinblastine—hematologic cancer	0.00149	0.00272	CbGbCtD
Pranlukast—CYSLTR1—blood—hematologic cancer	0.00148	0.0225	CbGeAlD
Pranlukast—CYP3A4—Vincristine—hematologic cancer	0.00147	0.00267	CbGbCtD
Pranlukast—NFKB1—bone marrow—hematologic cancer	0.00146	0.0222	CbGeAlD
Pranlukast—CYSLTR1—bone marrow—hematologic cancer	0.00143	0.0218	CbGeAlD
Pranlukast—CYP3A4—Etoposide—hematologic cancer	0.00134	0.00245	CbGbCtD
Pranlukast—NFKB1—lung—hematologic cancer	0.00132	0.0201	CbGeAlD
Pranlukast—CYSLTR1—lung—hematologic cancer	0.0013	0.0197	CbGeAlD
Pranlukast—NFKB1—testis—hematologic cancer	0.00125	0.019	CbGeAlD
Pranlukast—CYP3A4—Dexamethasone—hematologic cancer	0.0011	0.00201	CbGbCtD
Pranlukast—CYP3A4—Doxorubicin—hematologic cancer	0.000916	0.00167	CbGbCtD
Pranlukast—NFKB1—lymph node—hematologic cancer	0.000904	0.0137	CbGeAlD
Pranlukast—CYSLTR1—lymph node—hematologic cancer	0.000888	0.0135	CbGeAlD
Pranlukast—CYP2C9—hematopoietic system—hematologic cancer	0.000595	0.00905	CbGeAlD
Pranlukast—ABCC2—blood—hematologic cancer	0.000592	0.009	CbGeAlD
Pranlukast—ABCC2—testis—hematologic cancer	0.000489	0.00744	CbGeAlD
Pranlukast—Ospemifene—ESR1—hematologic cancer	0.000487	0.725	CrCbGaD
Pranlukast—CYP3A4—hematopoietic system—hematologic cancer	0.000454	0.0069	CbGeAlD
Pranlukast—CYP2C9—blood—hematologic cancer	0.000394	0.006	CbGeAlD
Pranlukast—ABCC2—lymph node—hematologic cancer	0.000355	0.0054	CbGeAlD
Pranlukast—CYP3A4—blood—hematologic cancer	0.000301	0.00457	CbGeAlD
Pranlukast—Candesartan—ABCB1—hematologic cancer	0.000184	0.275	CrCbGaD
Pranlukast—TNF—Developmental Biology—STAT3—hematologic cancer	2.77e-06	1.56e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—HES1—hematologic cancer	2.77e-06	1.55e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—MYC—hematologic cancer	2.77e-06	1.55e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—MTOR—hematologic cancer	2.77e-06	1.55e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PIK3CB—hematologic cancer	2.77e-06	1.55e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—NRAS—hematologic cancer	2.77e-06	1.55e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—TGFB1—hematologic cancer	2.76e-06	1.55e-05	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—KRAS—hematologic cancer	2.76e-06	1.55e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—NCOR1—hematologic cancer	2.75e-06	1.55e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CSF2—hematologic cancer	2.72e-06	1.53e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FGF1—hematologic cancer	2.72e-06	1.53e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FOXO1—hematologic cancer	2.68e-06	1.51e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PDGFRB—hematologic cancer	2.68e-06	1.5e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—FGF2—hematologic cancer	2.66e-06	1.49e-05	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—HRAS—hematologic cancer	2.66e-06	1.49e-05	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—KRAS—hematologic cancer	2.65e-06	1.49e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—MAPK3—hematologic cancer	2.65e-06	1.49e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—HRAS—hematologic cancer	2.64e-06	1.48e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—DCK—hematologic cancer	2.64e-06	1.48e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—B3GAT1—hematologic cancer	2.64e-06	1.48e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ASNS—hematologic cancer	2.64e-06	1.48e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PDGFRA—hematologic cancer	2.64e-06	1.48e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—FHL2—hematologic cancer	2.63e-06	1.48e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—JAK1—hematologic cancer	2.63e-06	1.47e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PRKCG—hematologic cancer	2.63e-06	1.47e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PIK3R1—hematologic cancer	2.62e-06	1.47e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CDKN1B—hematologic cancer	2.6e-06	1.46e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—AGRN—hematologic cancer	2.58e-06	1.45e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—TGFB1—hematologic cancer	2.57e-06	1.44e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—AKT1—hematologic cancer	2.57e-06	1.44e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—KRAS—hematologic cancer	2.56e-06	1.44e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—JAK2—hematologic cancer	2.55e-06	1.43e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CASP3—hematologic cancer	2.54e-06	1.43e-05	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—IL6—hematologic cancer	2.54e-06	1.43e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IL2—hematologic cancer	2.54e-06	1.43e-05	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—PIK3CA—hematologic cancer	2.54e-06	1.42e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—IL6—hematologic cancer	2.53e-06	1.42e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—BCL2—hematologic cancer	2.53e-06	1.42e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IFNG—hematologic cancer	2.5e-06	1.41e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—HDC—hematologic cancer	2.5e-06	1.41e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—MDM2—hematologic cancer	2.49e-06	1.4e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CCND1—hematologic cancer	2.48e-06	1.39e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—JUN—hematologic cancer	2.47e-06	1.39e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IL2RA—hematologic cancer	2.45e-06	1.38e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—IDH2—hematologic cancer	2.45e-06	1.37e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—HMMR—hematologic cancer	2.45e-06	1.37e-05	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—PIK3CA—hematologic cancer	2.43e-06	1.37e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TERT—hematologic cancer	2.43e-06	1.36e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—MTOR—hematologic cancer	2.42e-06	1.36e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PIK3CB—hematologic cancer	2.42e-06	1.36e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CD4—hematologic cancer	2.42e-06	1.36e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CDKN1A—hematologic cancer	2.4e-06	1.34e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PTEN—hematologic cancer	2.39e-06	1.34e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—KRAS—hematologic cancer	2.38e-06	1.34e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PDGFB—hematologic cancer	2.37e-06	1.33e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—PIK3CA—hematologic cancer	2.35e-06	1.32e-05	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—HRAS—hematologic cancer	2.35e-06	1.32e-05	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—AKT1—hematologic cancer	2.35e-06	1.32e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—MAPK8—hematologic cancer	2.34e-06	1.31e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—AKT1—hematologic cancer	2.33e-06	1.31e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TSC2—hematologic cancer	2.31e-06	1.3e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	2.31e-06	1.29e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ARNTL—hematologic cancer	2.3e-06	1.29e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CDA—hematologic cancer	2.29e-06	1.29e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—EP300—hematologic cancer	2.28e-06	1.28e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CDKN1B—hematologic cancer	2.27e-06	1.28e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—TP53—hematologic cancer	2.27e-06	1.28e-05	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—HRAS—hematologic cancer	2.25e-06	1.26e-05	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—IL6—hematologic cancer	2.25e-06	1.26e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CA9—hematologic cancer	2.24e-06	1.26e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ACP5—hematologic cancer	2.24e-06	1.26e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IL1B—hematologic cancer	2.23e-06	1.25e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FGFR3—hematologic cancer	2.23e-06	1.25e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IL2—hematologic cancer	2.22e-06	1.25e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—SRC—hematologic cancer	2.22e-06	1.24e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NCOR2—hematologic cancer	2.21e-06	1.24e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MAPK14—hematologic cancer	2.2e-06	1.24e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PC—hematologic cancer	2.2e-06	1.24e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—HRAS—hematologic cancer	2.17e-06	1.22e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—JUN—hematologic cancer	2.16e-06	1.21e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—ESR1—hematologic cancer	2.16e-06	1.21e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—VEGFA—hematologic cancer	2.16e-06	1.21e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—STAT3—hematologic cancer	2.14e-06	1.2e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FN1—hematologic cancer	2.14e-06	1.2e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—NRAS—hematologic cancer	2.13e-06	1.2e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GBA—hematologic cancer	2.13e-06	1.19e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—SLC35B2—hematologic cancer	2.13e-06	1.19e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—BAD—hematologic cancer	2.11e-06	1.18e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—NFKBIA—hematologic cancer	2.11e-06	1.18e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—IDH1—hematologic cancer	2.1e-06	1.18e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CDKN1A—hematologic cancer	2.1e-06	1.18e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PTEN—hematologic cancer	2.09e-06	1.18e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—NOTCH1—hematologic cancer	2.09e-06	1.17e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IL6—hematologic cancer	2.08e-06	1.17e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTO1—hematologic cancer	2.08e-06	1.17e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ABCC3—hematologic cancer	2.08e-06	1.17e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—TXN—hematologic cancer	2.08e-06	1.17e-05	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—AKT1—hematologic cancer	2.07e-06	1.16e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—MAPK8—hematologic cancer	2.05e-06	1.15e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CD80—hematologic cancer	2.05e-06	1.15e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—KIT—hematologic cancer	2.04e-06	1.15e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PIK3CG—hematologic cancer	2.04e-06	1.15e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—MAPK3—hematologic cancer	2.04e-06	1.15e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—SPHK1—hematologic cancer	2.04e-06	1.14e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—HRAS—hematologic cancer	2.02e-06	1.14e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PTPN11—hematologic cancer	2.01e-06	1.13e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—EP300—hematologic cancer	2e-06	1.12e-05	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—AKT1—hematologic cancer	1.99e-06	1.12e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—MYC—hematologic cancer	1.99e-06	1.12e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—TGFB1—hematologic cancer	1.98e-06	1.11e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—UGT1A1—hematologic cancer	1.96e-06	1.1e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—MTAP—hematologic cancer	1.95e-06	1.09e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CREB1—hematologic cancer	1.95e-06	1.09e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—SRC—hematologic cancer	1.94e-06	1.09e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—IL6—hematologic cancer	1.94e-06	1.09e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—BRAF—hematologic cancer	1.92e-06	1.08e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—AKT1—hematologic cancer	1.92e-06	1.08e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CCL2—hematologic cancer	1.9e-06	1.07e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—SLC22A1—hematologic cancer	1.9e-06	1.07e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CRABP1—hematologic cancer	1.9e-06	1.07e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IL6R—hematologic cancer	1.9e-06	1.07e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CREBBP—hematologic cancer	1.9e-06	1.06e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—STAT3—hematologic cancer	1.87e-06	1.05e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—NRAS—hematologic cancer	1.87e-06	1.05e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ALOX5—hematologic cancer	1.85e-06	1.04e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—KRAS—hematologic cancer	1.84e-06	1.03e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MAP2K1—hematologic cancer	1.81e-06	1.02e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PIK3CD—hematologic cancer	1.8e-06	1.01e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NUP98—hematologic cancer	1.8e-06	1.01e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—MAPK3—hematologic cancer	1.79e-06	1e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—AKT1—hematologic cancer	1.79e-06	1e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NCOA3—hematologic cancer	1.74e-06	9.78e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ADCY7—hematologic cancer	1.74e-06	9.78e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—FHL2—hematologic cancer	1.74e-06	9.74e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NUP214—hematologic cancer	1.73e-06	9.71e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—FGF2—hematologic cancer	1.72e-06	9.66e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.71e-06	9.61e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—AGRN—hematologic cancer	1.7e-06	9.55e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PIK3R1—hematologic cancer	1.7e-06	9.52e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ABCG2—hematologic cancer	1.7e-06	9.52e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—MTR—hematologic cancer	1.7e-06	9.52e-06	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—PIK3CA—hematologic cancer	1.69e-06	9.47e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ENO2—hematologic cancer	1.66e-06	9.33e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—JAK2—hematologic cancer	1.65e-06	9.26e-06	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—TP53—hematologic cancer	1.63e-06	9.16e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—HMMR—hematologic cancer	1.61e-06	9.06e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—IDH2—hematologic cancer	1.61e-06	9.06e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTT1—hematologic cancer	1.61e-06	9.05e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MDM2—hematologic cancer	1.61e-06	9.04e-06	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—KRAS—hematologic cancer	1.61e-06	9.02e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.59e-06	8.91e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—SDC1—hematologic cancer	1.58e-06	8.85e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MTOR—hematologic cancer	1.57e-06	8.79e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PIK3CB—hematologic cancer	1.57e-06	8.79e-06	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—HRAS—hematologic cancer	1.56e-06	8.76e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.52e-06	8.51e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.51e-06	8.45e-06	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IL6—hematologic cancer	1.49e-06	8.38e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.49e-06	8.34e-06	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—PIK3CA—hematologic cancer	1.48e-06	8.29e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CA9—hematologic cancer	1.48e-06	8.28e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ACP5—hematologic cancer	1.48e-06	8.28e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CDKN1B—hematologic cancer	1.47e-06	8.25e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.46e-06	8.17e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CASP3—hematologic cancer	1.44e-06	8.09e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IL2—hematologic cancer	1.44e-06	8.07e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.42e-06	7.98e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CCND1—hematologic cancer	1.4e-06	7.87e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—JUN—hematologic cancer	1.4e-06	7.85e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—IDH1—hematologic cancer	1.39e-06	7.79e-06	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—AKT1—hematologic cancer	1.38e-06	7.73e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.37e-06	7.7e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—TXN—hematologic cancer	1.37e-06	7.7e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.37e-06	7.7e-06	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—HRAS—hematologic cancer	1.37e-06	7.67e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CDKN1A—hematologic cancer	1.36e-06	7.61e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PTEN—hematologic cancer	1.35e-06	7.6e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.34e-06	7.54e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CD44—hematologic cancer	1.34e-06	7.52e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NQO1—hematologic cancer	1.34e-06	7.52e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MAPK8—hematologic cancer	1.32e-06	7.43e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.31e-06	7.37e-06	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IL6—hematologic cancer	1.31e-06	7.34e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—EP300—hematologic cancer	1.29e-06	7.25e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.29e-06	7.24e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CYCS—hematologic cancer	1.27e-06	7.12e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.26e-06	7.07e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—SRC—hematologic cancer	1.26e-06	7.05e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.25e-06	7.04e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.25e-06	7.04e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.22e-06	6.86e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—VEGFA—hematologic cancer	1.22e-06	6.86e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—STAT3—hematologic cancer	1.21e-06	6.79e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—NRAS—hematologic cancer	1.21e-06	6.78e-06	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—AKT1—hematologic cancer	1.21e-06	6.77e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NUP98—hematologic cancer	1.18e-06	6.65e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MAPK3—hematologic cancer	1.16e-06	6.49e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.15e-06	6.45e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.15e-06	6.45e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NUP214—hematologic cancer	1.14e-06	6.41e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.13e-06	6.37e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—MYC—hematologic cancer	1.12e-06	6.31e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TGFB1—hematologic cancer	1.12e-06	6.3e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—MTR—hematologic cancer	1.12e-06	6.28e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.12e-06	6.28e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.12e-06	6.27e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ENO2—hematologic cancer	1.1e-06	6.16e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.08e-06	6.07e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.06e-06	5.97e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.06e-06	5.94e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—SDC1—hematologic cancer	1.04e-06	5.84e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—KRAS—hematologic cancer	1.04e-06	5.83e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.03e-06	5.77e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.03e-06	5.77e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—PIK3CA—hematologic cancer	9.55e-07	5.36e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TP53—hematologic cancer	9.24e-07	5.18e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—MTHFR—hematologic cancer	9.08e-07	5.1e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NQO1—hematologic cancer	8.84e-07	4.96e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CD44—hematologic cancer	8.84e-07	4.96e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—HRAS—hematologic cancer	8.83e-07	4.96e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IL6—hematologic cancer	8.45e-07	4.75e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CYCS—hematologic cancer	8.36e-07	4.69e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	8.31e-07	4.67e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8e-07	4.49e-06	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—AKT1—hematologic cancer	7.8e-07	4.38e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PIK3CG—hematologic cancer	7.63e-07	4.28e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTP1—hematologic cancer	7.37e-07	4.14e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CREBBP—hematologic cancer	7.07e-07	3.97e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ABCB1—hematologic cancer	6.98e-07	3.92e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NCOR1—hematologic cancer	6.77e-07	3.8e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—GSTM1—hematologic cancer	6.77e-07	3.8e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PIK3CD—hematologic cancer	6.71e-07	3.76e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—ALB—hematologic cancer	6.62e-07	3.72e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PIK3R1—hematologic cancer	6.33e-07	3.55e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—MTHFR—hematologic cancer	5.99e-07	3.36e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PIK3CB—hematologic cancer	5.84e-07	3.28e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PTEN—hematologic cancer	5.05e-07	2.84e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PIK3CG—hematologic cancer	5.03e-07	2.82e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—EP300—hematologic cancer	4.82e-07	2.7e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CREBBP—hematologic cancer	4.66e-07	2.62e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PIK3CD—hematologic cancer	4.42e-07	2.48e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—ALB—hematologic cancer	4.37e-07	2.45e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.18e-07	2.34e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PIK3CB—hematologic cancer	3.85e-07	2.16e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PIK3CA—hematologic cancer	3.56e-07	2e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PTEN—hematologic cancer	3.33e-07	1.87e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—EP300—hematologic cancer	3.18e-07	1.78e-06	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—AKT1—hematologic cancer	2.91e-07	1.63e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.35e-07	1.32e-06	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—AKT1—hematologic cancer	1.92e-07	1.08e-06	CbGpPWpGaD
